Condition: Relapsed or Refractory Multiple Myeloma · Sponsor: Genentech, Inc.
The purpose of the study is to evaluate safety and tolerability of the combination of cevostamab plus elranatamab and also determine the recommended Phase II regimen (RP2R) for the study treatment. The study consists of a safety lead-in stage, and an expansion stage.
This description comes directly from the study's public registry record.
GO43979 https://forpatients.roche.com/ No attachments to email below. · 888-662-6728 (U.S. Only) · global-roche-genentech-trials@gene.com
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Always discuss trial participation with your own doctor first.
| Royal Prince Alfred Hospital | Camperdown, New South Wales, Australia | Recruiting |
| Calvary Mater Newcastle | Waratah, New South Wales, Australia | Recruiting |
| Royal Adelaide Hospital;Haematology Clinical Trials Unit | Adelaide, South Australia, Australia | Recruiting |
| St. Vincent's Hospital Melbourne | Melbourne, Victoria, Australia | Recruiting |
| The Alfred Hospital | Prahan, Victoria, Australia | Recruiting |
| The Chaim Sheba Medical Center - PPDS | Ramat Gan, Central District, Israel | Recruiting |
| Rambam Health Care Campus | Haifa, Israel | Recruiting |
| Hadassah University Hospital - Ein Kerem | Jerusalem, Israel | Recruiting |
| Tel Aviv Sourasky Medical Center PPDS | Tel Aviv, Israel | Recruiting |
| The Catholic University of Korea - Seoul St. Mary's Hospital (Kangnam St. Mary's Hospital) | Seocho, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| Severance Hospital, Yonsei University Health System | Seoul, South Korea | Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05927571